Abstract
A large body of evidence indicates that guanosine 3’,5’-cyclic monophosphate (cGMP) plays an essential role in vasorelaxant actions of various agents such as atrial natriuretic factor (ANF), nitrogen oxide containing compounds (e.g., nitroprusside) and endothelium dependent vasodilators (e.g., acetylcholine) (1). These agents elevate cGMP by stimulating either soluble or particulate guanylate cyclase (1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 78: 1–5, 1986.
Beavo JA. Multiple isozymes of cyclic nucleotide phosphodiesterase. Adu Second Messenger Phosphoprotein Res 22: 1–38, 1988.
Lorenz KL, Wells JN. Potentiation of the effects of sodium nitroprusside and of isoproterenol by selective phosphodiesterase inhibitors. Mol Pharmacol 23: 424–430, 1983.
Hidaka H, Endo T. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterases—basic and potential clinical applications. Adv Cyclic Nucleotide Res 16: 245–259, 1984.
Lugnier C, Schoeffter P, LeBec A, Strouthou E, Stoclet JC. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35: 1743–1751, 1986.
Ahn HS, Crim W, Romano M, Moroney S, Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases (PDEs) of rabbit and pig aorta. Pharmacologist 29: 522, 1987.
Hagiware M, Endo T, Hidaka H. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol 33: 453–457, 1984.
Bergstrand H, Kristoffersson J, Lundquist B, Schurmann A. Effects of antiallergic agents, compounds 48/80, and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3’,5’-monophosphate and guanosine cyclic 3’5’monophosphate phosphodiesterases. Mol Pharmacol 13: 38–43, 1977.
Ahn HS, Crim W, Romano M, Moroney SJ, Sybertz EJ, Pitts B. Calmodulin dependent phosphodiesterase (CaM-PDE) and cyclic GMP specific PDE (cG-PDE) distribution and response to inhibitors in aorta and non-vascular tissues. Pharmacologist 30: A213, 1988.
Hansen RS, Beavo AJ. Differential recognition of calmodulinenzyme complexes by a conformation-specific anti-calmodulin monoclonal antibody. JBiol Chem 261: 14636–14645, 1986.
Ahn HS, Crim W, Romano M, Sybertz EJ, Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 38: 3331–3339, 1989.
Ahn HS, Eardley D, Watkins R, Prioli N. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism. Biochem Pharmacol 34: 1113–1121, 1986.
Ahn HS, Crim W, Pitts B, Sybertz EJ. Ca/CaM-stimulated and cGMP specific phosphodiesterases: tissue distribution, drug sensitivity and regulation of cGMP levels. Adv Second Messenger Phosphoprotein Res, Vol. 24, In Press, 1990.
Sharma RK, Wang JH. Isolation of bovine brain calmodulindependent cyclic nucleotide phosphodiesterase isozyme. Methods in Enzymology 159: 582–594, 1988.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Plenum Press, New York
About this chapter
Cite this chapter
Ahn, H.S., Foster, M., Cable, M., Pitts, B.J.R., Sybertz, E.J. (1991). Ca/CaM-Stimulated and cGMP-Specific Phosphodiesterases in Vascular and Non-Vascular Tissues. In: Cox, R.H. (eds) Cellular and Molecular Mechanisms in Hypertension. Advances in Experimental Medicine and Biology, vol 308. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-6015-5_15
Download citation
DOI: https://doi.org/10.1007/978-1-4684-6015-5_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-6017-9
Online ISBN: 978-1-4684-6015-5
eBook Packages: Springer Book Archive